Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

ELAN reports 3% revenue growth and raises full-year guidance

ELAN's Q1 2023 performance reflects a mix of successes and challenges. The company's U.S. pet health business shows improvement, while international segments face pressures. The successful completion of the Bayer ERP system integration significantly benefits growth. Analyst inquiries highlight areas of concern and scrutiny for the company.

Elanco Animal Health Exceeds Q2 Guidance, Prepares for Future Growth

Elanco Animal Health's Q2 2023 earnings call highlighted strong performance, raised guidance, and confidence in late-stage potential blockbuster products. While facing challenges such as revenue decline and slower pet market conditions in certain regions, the company is focused on sustained innovation and preparing for significant growth opportunities in the future.

Elanco reports strong Q3 performance, anticipates challenges and opportunities

Elanco's Q3 performance exceeded expectations, driven by international growth and innovation. The company faces challenges in the livestock segment but sees opportunities in new product launches and market growth. Key uncertainties for 2024 include competition, regulatory dynamics, and macroeconomic headwinds.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Credit Suisse

Elanco Animal Health Incorporated's (ELAN) CEO Jeff Simmons on Credit Suisse 29th Annual Virtual Healthcare Conference - Quick Version Earnings Call Transcript

Elanco Animal Health Incorporated's (ELAN) CEO Jeffrey Simmons on Q3 2020 Results - Earnings Call Transcript

Elanco Animal Health posted third-quarter earnings that edged views after completing its big Bayer Animal Health acquisition, but its sales and sales guidance lagged views. ELAN stock fell.

Elanco Animal Health Earnings Mixed, Sales Guidance Lags Expectations

  Shares of Elanco Animal Health (NYSE:ELAN) rose 0.1% in pre-market trading after the company reported Q3 results.

Elanco Animal Health: Q3 Earnings Insights

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the third quarter of 2020 and provided guidance for the fourth quarter of 2020. The results reflect the inclusion of the Bayer Animal Health business that Elanco acquired on August 1, 2020. "In the third quarter, Elanco executed with discipline and urgency to deliver on our stated expectations for the quarter, achieving results at the high end of our guidance while bolsteri

Elanco Animal Health Reports Third Quarter 2020 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET. A live audio webcast will be available on the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately one year. ABOUT ELANCO Elanco Animal Health (NYSE: ELAN) i

Elanco to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--With the U.S. Food and Drug Administration (FDA) approval of Elura™ (capromorelin oral solution), a new prescription medication to manage weight loss in cats with chronic kidney disease (CKD), Elanco Animal Health (NYSE: ELAN) expands its feline offerings while addressing an unmet need in an increasingly common condition as cats age. CKD causes progressive weight loss due to a variety of factors including decreased appetite, malabsorption, and increased energy

Elanco's Elura™ (capromorelin oral solution) Gains U.S. Approval

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced its first sustainability commitments, just two years after becoming an independent company. The decade-long commitments support the SDGs, address societal challenges and underscore Elanco's role in improving the health of animals, which also improves the health of people and the planet. Today, the company is issuing three Healthy Purpose Pledges to drive sustainable change by 2030, including: Prote

Elanco Releases Healthy Purpose™ 2030 Sustainability Commitments to Improve Health of Animals, People and Planet

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (“Elanco”) (NYSE: ELAN) has received a notification of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (“TRC Capital”) to purchase up to 4,000,000 shares of Elanco common stock, representing approximately 1.00% of the outstanding shares of Elanco common stock. TRC Capital’s offer price of $26.45 per share is approximately 4.5% lower than the $27.70 closing price per share of Elanco common stock on the

Elanco Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2020 financial results on Friday, November 6, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media and the general public can access a live webcast of the conference call through the link that will be posted on Elanco

Elanco Confirms Date and Conference Call for Third Quarter 2020 Financial Results Announcement

Palantir Technologies

Visa

You don't need to start with a fortune to chart a path toward financial independence.

4 Great Stocks You Can Buy With $300

Hedge fund Sachem Head Capital Management has built a $1.2 billion stake in Elanco Animal Health Inc and plans to push for changes at the company that makes medicines and vaccinations for pets and livestock, a person familiar with the matter said on Wednesday.

Sachem Head takes $1.2 billion position in Elanco, stock price surges

Elanco Animal Health Inc. ELAN, -1.10% said Wednesday it is restructuring its business just two months after closing the acquisition of Bayer Animal Health. The Greenfield, Indiana-based company said it expects to cut 900 jobs across nearly 40 countries, mostly in sales and marketing, but also in R&D, manufacturing and quality, and back office support.

Elanco Animal Health to cut 900 jobs in 40 countries in restructuring following acquisition of Bayer Animal Health

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE:ELAN) today announced its first business restructuring just two months following the closing of its acquisition of Bayer Animal Health. The company also noted it has started to de-lever by making a $100 million payment on its term loan. Elanco leadership has quickly evaluated the capabilities, structure and staffing of the combined business required to meet its goal of being an agile, fit-for-purpose global leader dedica

Elanco Announces Restructuring to Drive Synergies From Bayer Animal Health Acquisition

CrowdStrike

SSR Mining

A vacillating stock market can be your friend if you have cash at the ready and a long-term mindset.

Got $300? 4 Great Stocks to Buy in a Volatile Market

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020.

Elanco to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference

The acquisition of Bayer Animal Health establishes Elanco as the second-largest animal health company in the world.

This Pet Stock Just Bought an Animal Health Business for $7.6 Billion

Elanco Animal Health (NYSE: ELAN) shares are trading higher on Thursday after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and announced a price target of $31 per share.

Why Elanco Animal Health's Stock Is Trading Higher Today

Elanco Animal Health Inc (NYSE: ELAN) shares are trading higher on Tuesday after Goldman Sachs reinstated a Buy rating on the stock and announced a price target of $26.50 per share.

Why Elanco Animal's Stock Is Trading Higher Today

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health.

Elanco Closes Acquisition of Bayer Animal Health

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q2 2020 Results - Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 350.00% and 5.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings and Revenue Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2020.

Elanco Animal Health Reports 2020 Second Quarter Results

New York, New York--(Newsfile Corp. - July 20, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated  ("Elanco" or "the Company") (NYSE: ELAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Elanco securities between January 10, 2020 and May 6, 2020, inclusive (the ''Class Period'').

ELAN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Elanco Animal Health Incorporated and Lead Plaintiff Deadline: July 20, 2020

Los Angeles, California--(Newsfile Corp. - July 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN) ("Elanco" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Elanco Animal Health Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for Elanco Animal Health Inc Stock (ELAN)